import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "where-to-buy-retatrutide-research-guide",
  title: "Where to Buy Retatrutide: A Researcher's Sourcing Guide (2026)",
  description:
    "Retatrutide is the most potent triple agonist peptide in active research — GLP-1, GIP, and glucagon receptor activation in one molecule. This guide covers purity requirements, COA red flags, cold-chain standards, and what to demand from a verified source.",
  category: "Quality & Testing",
  readMinutes: 10,
  publishedAt: "2026-06-06",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Retatrutide (LY3437943) is a synthetic 36-amino acid peptide that activates three receptors simultaneously: GLP-1R, GIPR, and the glucagon receptor. Phase 2 clinical data published in the New England Journal of Medicine demonstrated average weight reductions exceeding 24% at 48 weeks — the largest documented reduction of any pharmacological agent studied to date in non-surgical weight loss research.",
    },
    {
      type: "paragraph",
      text: "For researchers studying metabolic syndrome, obesity biology, hepatic steatosis, or the comparative pharmacology of incretin-axis agonists, retatrutide is the current frontier compound. Its sourcing, however, presents challenges that differ significantly from older, simpler peptides like BPC-157 or ipamorelin.",
    },
    {
      type: "heading",
      text: "Why Retatrutide Sourcing Is Particularly High-Stakes",
    },
    {
      type: "paragraph",
      text: "Retatrutide is a 36-residue peptide with a fatty acid modification at the C-terminus — a structural feature that dramatically extends its half-life through albumin binding but also makes synthesis far more complex than a simple linear peptide. The compound must be correctly acylated, correctly folded, and purified to remove synthesis byproducts that could include truncated sequences, incorrect acylation variants, and diastereomers.",
    },
    {
      type: "paragraph",
      text: "In a market where many vendors simply relabel crude synthesis batches from low-cost CMOs, the probability of receiving a correctly structured retatrutide molecule at the labeled purity is substantially lower than for simpler research peptides. An HPLC COA showing ≥98% purity with an accompanying mass spec (ESI-MS or MALDI-TOF) confirming the correct molecular weight of ~4,474 Da is the minimum standard for research use.",
    },
    {
      type: "heading",
      text: "What the COA Must Include",
    },
    {
      type: "list",
      items: [
        "HPLC purity ≥98% with chromatogram showing the area-under-curve calculation",
        "Mass spectrometry (ESI-MS or MALDI-TOF) confirming MW ~4,474 Da",
        "Lot number traceable to the specific synthesis batch",
        "Endotoxin (LAL) test result — critical for injectable research applications",
        "Water content (Karl Fischer) if vial weight is used to calculate molarity",
        "Certificate issued by a third-party analytical lab, not the vendor's in-house lab",
      ],
    },
    {
      type: "paragraph",
      text: "If a supplier cannot provide mass spec data for retatrutide, the COA is incomplete. HPLC alone cannot confirm that the dominant peak in the chromatogram is the correct molecular species — it only confirms relative area. A correctly acylated retatrutide and an incorrectly acylated analog may co-elute under some gradient conditions.",
    },
    {
      type: "heading",
      text: "Cold Chain Requirements",
    },
    {
      type: "paragraph",
      text: "Retatrutide contains a C18 fatty acid chain modification that can degrade under thermal stress. The compound should be stored lyophilized at -20°C or below. Shipping must include dry ice or validated cold packs capable of maintaining ≤-15°C for the transit duration — not simply 'refrigerated' packaging. Vendors who ship retatrutide with standard ice packs in summer months are providing a compromised product.",
    },
    {
      type: "callout",
      text: "Research note: Once reconstituted in sterile water or bacteriostatic water, retatrutide solutions should be stored at 4°C and used within 28–30 days. Freeze-thaw cycles should be minimized; aliquot into single-use volumes before freezing if long-term storage is required.",
    },
    {
      type: "heading",
      text: "Vendor Red Flags Specific to Retatrutide",
    },
    {
      type: "list",
      items: [
        "Generic COA without retatrutide-specific mass spec data",
        "Pricing significantly below $180–250 per 5mg vial — retatrutide synthesis cost cannot support lower margins legitimately",
        "No LAL (endotoxin) test result on COA",
        "Claims of 'pharmaceutical grade' without third-party lab documentation",
        "Vendor does not disclose the synthesis facility or country of manufacture",
        "Minimum order quantities waived with no explanation — bulk dumping of offgrade lots",
        "Website shows no lot-specific COA download capability",
      ],
    },
    {
      type: "heading",
      text: "Research Context: What Retatrutide Is Being Used to Study",
    },
    {
      type: "paragraph",
      text: "The Phase 2 NEJM data covered 338 adults with obesity (BMI ≥27). At the highest dose studied (12 mg weekly), participants lost 24.2% of body weight over 48 weeks. Crucially, retatrutide's glucagon receptor activity drives additional hepatic glucose output suppression and fatty acid oxidation — mechanisms not present in semaglutide or tirzepatide.",
    },
    {
      type: "paragraph",
      text: "Active research areas as of 2026 include: comparative efficacy versus dual agonists in diet-induced obesity models, hepatic steatosis reversal via glucagon-driven FFA oxidation, skeletal muscle preservation protocols when combined with resistance training paradigms, and cardiovascular outcomes in metabolically compromised subjects.",
    },
    {
      type: "subheading",
      text: "Dosing Reference (Published Clinical Data)",
    },
    {
      type: "paragraph",
      text: "The NEJM Phase 2 study used once-weekly subcutaneous injections with a titration schedule: 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg or 12 mg depending on cohort assignment. In animal models, dosing is typically expressed in nmol/kg. Researchers should consult the published pharmacokinetic data (Urva et al., 2023, NEJM) for allometric scaling guidance.",
    },
    {
      type: "heading",
      text: "What Nexphoria Provides",
    },
    {
      type: "paragraph",
      text: "Nexphoria supplies retatrutide as a lyophilized research peptide with lot-specific COA from an independent analytical laboratory. Every lot includes HPLC purity data, ESI-MS molecular weight confirmation, and LAL endotoxin testing. Shipment is cold-chain handled with dry ice packaging verified against ambient temperature data for transit duration.",
    },
    {
      type: "paragraph",
      text: "Retatrutide is supplied strictly for research purposes. It is not approved for human therapeutic use by the FDA or any equivalent regulatory body. All purchases are restricted to verified research contexts.",
    },
    {
      type: "disclaimer",
      text: "This article is for informational and educational purposes only. Retatrutide is a research compound not approved for human use. This content does not constitute medical advice. Always conduct research in compliance with applicable institutional and regulatory guidelines.",
    },
  ],
};
